Used in pharmaceutical research as a potent PPARγ agonist, this compound shows promise in the development of insulin-sensitizing agents for treating type 2 diabetes. It enhances glucose uptake in adipose and muscle tissues by modulating gene expression involved in glucose and lipid metabolism. Due to its structural features, including the thiazolidinedione core and biphenyl moiety, it exhibits strong binding affinity to the PPARγ receptor, making it a candidate for improving insulin resistance. Studies also explore its anti-inflammatory and anti-atherogenic effects, suggesting potential in managing metabolic syndrome and related cardiovascular complications. Its nitro-substituted biphenyl group contributes to improved pharmacokinetic properties and receptor selectivity.